A Multi-centre, Prospective, Non-interventional Study to Describe the Efficacy of a Continuous up to 24-week Treatment of Diphereline 3.75mg Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Triptorelin (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Acronyms DIE-NIS
- Sponsors Ipsen
- 24 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2016 Planned End Date changed from 1 Jun 2018 to 1 Jul 2018.
- 28 Jul 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2018.